{"title":"甲氨蝶呤治疗持续性滋养细胞疾病预防磨牙后绒毛膜癌","authors":"Maeda Kazuo","doi":"10.46619/joccr.2019.2-1047","DOIUrl":null,"url":null,"abstract":"Aim: Prevention of post molar choriocarcinoma. Methods: 70 mg Methotrexate (MTX) was administered all post molar cases, whose urinary pregnancy test was negative, while 200-300 mg MTX was administered to two persistent trophoblastic disease, whose pregnancy test was positive by human chorionic gonadotropin (hCG). Control was 37 post molar cases, who received no MTX. Post molar examination were repeated in both groups. Results: No choriocarcinoma developed in 107 MTX group, while 3 cases developed choriocarcinoma in 37 nonMTX group. Choriocarcinoma case number was significantly less in MTX groups.","PeriodicalId":73665,"journal":{"name":"Journal of clinical cases & reports","volume":"61 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-molar Choriocarcinoma Prevention with MTX Treatment of Persistent Trophoblastic Disease\",\"authors\":\"Maeda Kazuo\",\"doi\":\"10.46619/joccr.2019.2-1047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Prevention of post molar choriocarcinoma. Methods: 70 mg Methotrexate (MTX) was administered all post molar cases, whose urinary pregnancy test was negative, while 200-300 mg MTX was administered to two persistent trophoblastic disease, whose pregnancy test was positive by human chorionic gonadotropin (hCG). Control was 37 post molar cases, who received no MTX. Post molar examination were repeated in both groups. Results: No choriocarcinoma developed in 107 MTX group, while 3 cases developed choriocarcinoma in 37 nonMTX group. Choriocarcinoma case number was significantly less in MTX groups.\",\"PeriodicalId\":73665,\"journal\":{\"name\":\"Journal of clinical cases & reports\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of clinical cases & reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46619/joccr.2019.2-1047\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical cases & reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46619/joccr.2019.2-1047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Post-molar Choriocarcinoma Prevention with MTX Treatment of Persistent Trophoblastic Disease
Aim: Prevention of post molar choriocarcinoma. Methods: 70 mg Methotrexate (MTX) was administered all post molar cases, whose urinary pregnancy test was negative, while 200-300 mg MTX was administered to two persistent trophoblastic disease, whose pregnancy test was positive by human chorionic gonadotropin (hCG). Control was 37 post molar cases, who received no MTX. Post molar examination were repeated in both groups. Results: No choriocarcinoma developed in 107 MTX group, while 3 cases developed choriocarcinoma in 37 nonMTX group. Choriocarcinoma case number was significantly less in MTX groups.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
